What Is Mounjaro, and Why Is It Different from Other Weight-Loss Medicines?

What the SURMOUNT programme showed, and why regulators took notice

Tirzepatide's path to UK approval was built on a large clinical programme called SURMOUNT. The headline trial, SURMOUNT-1, enrolled 2,539 adults with obesity or overweight and at least one weight-related condition but without type 2 diabetes. After 72 weeks, those on the 15 mg dose had lost an average of around 20–21% of their body weight compared with the placebo group, a result that placed tirzepatide above any previously licensed weight-loss injection in head-to-head evidence. NICE cited this data when recommending tirzepatide in its Technology Appraisal TA1026, published in December 2024, the formal recommendation that opened the door to NHS prescribing in England for eligible patients.

That recommendation matters for a simple reason: TA1026 is not just an endorsement of the trial numbers; it is NICE's judgement that tirzepatide represents value for the NHS against its cost. Reaching that conclusion requires scrutiny of methodology, comparator data and longer-term modelling. The evidence held up. For the SURMOUNT-5 trial (a direct head-to-head comparison with semaglutide 2.4 mg published in the New England Journal of Medicine in 2025) tirzepatide produced a greater average weight reduction over 72 weeks among adults with obesity and no diabetes. These are not small studies or short timeframes.

Worth noting: trial results describe averages across a population. Individual responses vary, and no medicine guarantees a particular outcome for any one person.

Two receptors, one injection: what makes tirzepatide structurally different

Most GLP-1 medicines on the market activate a single receptor pathway. Tirzepatide activates two: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Both are involved in regulating appetite, blood sugar and how quickly food moves through the stomach. Switching on both simultaneously appears to produce a stronger appetite-suppressing effect than either pathway alone, which is the working explanation researchers offer for the larger average weight reductions seen in trials.

For a thorough breakdown of the pharmacology, this page explains GIP's specific role in Mounjaro and why it matters. The short version: GIP receptors are found in fat tissue and the brain as well as the gut, so their activation adds effects that a pure GLP-1 agonist does not replicate. The clinical result is a medicine that produces meaningfully greater average reductions in body weight than semaglutide 2.4 mg, as the SURMOUNT-5 data confirmed directly.

Each Mounjaro KwikPen contains four weekly doses and is stored in the fridge, most people keep it in the door, alongside other injectables, and set a weekly day that becomes routine quickly. The injection goes into the abdomen, thigh or upper arm; you rotate the site each week per the patient information leaflet.

Who Mounjaro is licensed for, and what eligibility actually involves

Under its UK marketing authorisation, Mounjaro is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition, such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance. The licence covers weight management alongside a reduced-calorie diet and increased physical activity; it is not a standalone intervention.

NICE's TA1026 recommendation for NHS use sets a higher bar than the licence alone: BMI 35 or above with at least one qualifying comorbidity, phased in by cohort through to 2027. Private prescribing follows the licensed criteria, not the NHS cohort timetable, but a prescriber still needs to assess whether the medicine is clinically appropriate for you specifically. BMI alone is not sufficient, your full health picture matters. The tirzepatide overview covers the eligibility detail more fully, including what the NHS phased rollout means in practice.

If you are curious about what Mounjaro costs through a private pharmacy, that page gives honest context on how private pricing is structured. Treatment is a prescription-only medicine; a consultation precedes any prescription, and that consultation has genuine clinical content, not a checkbox exercise.

The Black Triangle and what ongoing monitoring means in practice

Mounjaro's ▼ designation appears on the packaging and in the patient information leaflet. It signals that the MHRA has designated tirzepatide as a medicine subject to additional monitoring, standard for newer medicines where the clinical trial evidence, though extensive, is necessarily shorter than decades of post-market real-world data. If you are new to tirzepatide and want to understand what Mounjaro is and how it works before reading further, that page is a useful starting point. The Black Triangle does not mean the medicine is unsafe; it means the regulator actively collects more post-market information than it does for established medicines.

In practice, this has two implications. First, healthcare professionals and patients are encouraged to report any suspected side effects via the MHRA's Yellow Card scheme, which helps build the long-term safety picture. Second, it reinforces why Mounjaro must be obtained through a proper clinical route: a prescriber who knows your full medical history can weigh the monitoring data against your individual circumstances. The Mounjaro treatment page outlines how that process works at nume, including the clinical review that happens before every order, not just the first. If you have questions specific to your situation before starting, our team is available seven days a week.

For anyone ready to take the next step, starting a free consultation is the right place to begin.